While rapid positive advances in medical science roll out, global healthcare systems still face an important opportunity for transformation: a prevention healthcare revolution.
As of late November 2024, the US Food & Drug Administration had recorded 46 voluntary drug recalls in the United States during the year, down slightly from previous years – an indicatio
This year has seen a rapid rise in the demand for Ozempic due to it being popularised by celebrity endorsements online, leading to a shortage of product.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
